Article
Author: Lepage, Marie-Noelle ; Feeney, Elizabeth ; Munt, Jennifer E ; Torrelles, Jordi B ; Bedinger, Daniel ; Troup, Camille ; Li, Kan ; Tomaras, Georgia D ; Martinez-Sobrido, Luis ; Khan, Sarwat ; Saphire, Erica Ollmann ; Bukreyev, Alexander ; Peters, Bjoern ; Kuzmina, Natalia ; Palser, Anne ; Baric, Ralph S ; Gagnon, Luc ; Ha, Brendan ; Schendel, Sharon L ; Reece, Stephen ; Ye, Chengjin ; St-Amant, Natalie ; Yu, Xiaoying ; Gambiez, Anaïs ; Halfmann, Peter J ; Pino, Paula A ; Huntwork, Richard H C ; Callaway, Heather M ; Abraha, Milite ; Osei-Twum, Mary ; Horn, Gillian Q ; Hastie, Kathryn M ; Hicks, Amberlee ; Kawaoka, Yoshihiro ; Dennison, S Moses ; Periasamy, Sivakumar ; Scobey, Trevor ; Kellam, Paul ; Germann, Timothy ; Mallory, Michael ; Park, Jun-Gyu ; Maingot, Billie ; Li, Haoyang ; Mahita, Jarjapu ; Maddocks, Melissa
The Coronavirus Immunotherapeutic Consortium (CoVIC) conducted side-by-side comparisons of over 400 anti-SARS-CoV-2 spike therapeutic antibody candidates contributed by large and small companies as well as academic groups on multiple continents. Nine reference labs analyzed antibody features, including in vivo protection in a mouse model of infection, spike protein affinity, high-resolution epitope binning, ACE-2 binding blockage, structures, and neutralization of pseudovirus and authentic virus infection, to build a publicly accessible dataset in the database CoVIC-DB. High-throughput, high-resolution binning of CoVIC antibodies defines a broad and predictive landscape of antibody epitopes on the SARS-CoV-2 spike protein and identifies features associated with durable potency against multiple SARS-CoV-2 variants of concern and high in vivo efficacy. Results of the CoVIC studies provide a guide for selecting effective and durable antibody therapeutics and for immunogen design as well as providing a framework for rapid response to future viral disease outbreaks.